✦ LIBER ✦

A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication

✍ Scribed by Eric P. Brass; Leslie T. Cooper; Roger E. Morgan; William R. Hiatt

Book ID: 116713373
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 558 KB
Volume: 55
Category: Article
ISSN: 1097-6809
DOI: 10.1016/j.jvs.2011.09.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A double-blind dose-ranging study of ris

A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group)

✍ M. Shiraki; M. Fukunaga; K. Kushida; H. Kishimoto; Y. Taketani; H. Minaguchi; T. 📂 Article 📅 2003 🏛 Springer-Verlag 🌐 English ⚖ 320 KB

Regional angiogenesis with vascular endo

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase ii randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication

✍ S. Rajagopalan; E.R. Mohler; R.J. Lederman 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 32 KB

Regional angiogenesis with vascular endo

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: A phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication

✍ Rajagopalan, S.; Mohler, E.R.; Lederman, R.J. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 33 KB

BAY 59-7939: an oral, direct Factor Xa i

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

✍ A. G. G. TURPIE; W. D. FISHER; K. A. BAUER; L. M. KWONG; M. W. IRWIN; P. KÄLEBO; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

Ocrelizumab, a humanized anti-CD20 monoc

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

✍ Mark C. Genovese; Jeffrey L. Kaine; Mitchell B. Lowenstein; José Del Giudice; An 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 623 KB

A Phase II study of 153Sm-EDTMP and high

A Phase II study of 153Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma

✍ Angela Dispenzieri; Gregory A. Wiseman; Martha Q. Lacy; Suzanne R. Hayman; Shaji 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB 👁 2 views